Biogen Names Priya Singhal as Executive Vice President, Head of Development
05 January 2023 - 11:30PM
Biogen Names Priya Singhal as Executive Vice President, Head of
Development
Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D.,
M.P.H., currently Head of Global Safety and Regulatory Sciences and
Interim Head of Research & Development (R&D), has been
promoted to Executive Vice President, Head of Development,
following a decision to separate Research and Development into two
distinct functions that will both report directly to the CEO.
In addition, Biogen has initiated a search for a new Executive
Vice President, Head of Research; Dr. Singhal will serve as interim
head of Research until a new leader is named.
“Throughout her tenure at Biogen, Priya has demonstrated
excellent leadership and judgement. In this new role, Priya will
focus on delivering on our development programs while working
closely with a new dedicated head of Research to strengthen
Biogen’s translational science capabilities,” said Christopher A.
Viehbacher, President and Chief Executive Officer of Biogen. “We
believe having two dedicated leaders will enhance productivity in
bringing to patients worldwide medicines to treat some of the most
challenging diseases, while assuring better risk management and
resource stewardship.”
Priya Singhal, M.D., M.P.H. – Dr. Singhal most recently served
as Senior Vice President and Head of Global Safety and Regulatory
Sciences and Interim Head of R&D at Biogen. She also had
oversight of Japan and China R&D. Dr. Singhal rejoined Biogen
in 2020, having previously led Biogen’s Global Safety and Benefit
Risk Management as the interim co-lead and Senior Vice President of
Global Development. In this role she managed the worldwide
benefit-risk strategy for the portfolio as well as for the filings
and approvals of six products. She joined Biogen in late 2012 as
Vice President Clinical Trials and Benefit-Risk Management. Prior
to her return to Biogen, Dr. Singhal served as Head of R&D and
Manufacturing at Zafgen Inc., a clinical-stage biopharmaceutical
company leveraging its proprietary knowledge of MetAP2 systems
biology to develop novel therapies for patients affected by a range
of metabolic diseases. From 2008-2012 she was at Vertex
Pharmaceuticals where she served as the Vice President, Medical
Affairs and held roles of increasing seniority in Global Patient
Safety. She began her drug-development career at Millennium
Pharmaceuticals where she led benefit-risk for Velcade and two
compounds in the development portfolio.
Preceding her career in the biotechnology Industry, Dr. Singhal
completed her M.P.H. in International Health at Harvard School of
Public Health and obtained her training in Internal Medicine in
Mumbai, India.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has a
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and developed the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing one of the
industry’s most diversified pipelines in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This news release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, relating to: our strategy and plans;
potential of, and expectations for, our commercial business and
pipeline programs; capital allocation and investment strategy;
clinical development programs, clinical trials, and data readouts
and presentations; the expected benefits from Ms. Singhal’s
appointment as Executive Vice President, Head of Development; and
the expected benefits from the separation of Research and
Development into two distinct functions. These forward-looking
statements may be accompanied by such words as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “potential,” “possible,” “prospect,”
“will,” “would,” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements
or the scientific data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including: our dependence on sales from our
products; uncertainty of long-term success in developing,
licensing, or acquiring other product candidates or additional
indications for existing products; failure to compete effectively
due to significant product competition in the markets for our
products; failure to successfully execute or realize the
anticipated benefits of our strategic and growth initiatives;
difficulties in obtaining and maintaining adequate coverage,
pricing, and reimbursement for our products; our dependence on
collaborators, joint venture partners, and other third parties for
the development, regulatory approval, and commercialization of
products and other aspects of our business, which are outside of
our full control; the potential impact of the conflict in Ukraine;
risks associated with current and potential future healthcare
reforms; risks related to commercialization of biosimilars; risks
relating to the distribution and sale by third parties of
counterfeit or unfit versions of our products; risks relating to
the use of social media for our business; failure to obtain,
protect, and enforce our data, intellectual property, and other
proprietary rights and the risks and uncertainties relating to
intellectual property claims and challenges; the risk that positive
results in a clinical trial may not be replicated in subsequent or
confirmatory trials or success in early stage clinical trials may
not be predictive of results in later stage or large scale clinical
trials or trials in other potential indications; risks associated
with clinical trials, including our ability to adequately manage
clinical activities, unexpected concerns that may arise from
additional data or analysis obtained during clinical trials,
regulatory authorities may require additional information or
further studies, or may fail to approve or may delay approval of
our drug candidates; the occurrence of adverse safety events,
restrictions on use with our products, or product liability claims;
risks relating to technology failures or breaches; problems with
our manufacturing processes; risks relating to management and
personnel changes, including attracting and retaining personnel;
failure to comply with legal and regulatory requirements; the risks
of doing business internationally, including currency exchange rate
fluctuations; risks relating to investment in our manufacturing
capacity; the direct and indirect impacts of the ongoing COVID-19
pandemic on our business, results of operations, and financial
condition; fluctuations in our operating results; risks related to
investment in properties; the market, interest, and credit risks
associated with our investment portfolio; risks relating to share
repurchase programs; risks relating to access to capital and credit
markets; risks related to indebtedness; change in control
provisions in certain of our collaboration agreements; fluctuations
in our effective tax rate; environmental risks; and any other risks
and uncertainties that are described in other reports we have filed
with the U.S. Securities and Exchange Commission.
These statements are based on our current beliefs and
expectations and speak only as of the date of this news release. We
do not undertake any obligation to publicly update any
forward-looking statements.
MEDIA CONTACT:BiogenJack Cox+ 1 210 544
7920public.affairs@biogen.com |
INVESTOR CONTACT:BiogenMike Hencke+1 781 464
2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024